[New drug approvals: Ripretinib for advanced gastrointestinal stromal tumors (GIST) in fourth or later-line therapy]

Bull Cancer. 2022 Mar;109(3):250-252. doi: 10.1016/j.bulcan.2022.01.002. Epub 2022 Jan 31.
[Article in French]
No abstract available

Keywords: Advanced GIST; GIST avancée; Inhibiteur de tyrosine kinase; KIT; PDGFRA; Tyrosine kinase inhibitor.

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Drug Approval
  • Drug Resistance, Neoplasm
  • Gastrointestinal Neoplasms* / drug therapy
  • Gastrointestinal Neoplasms* / pathology
  • Gastrointestinal Stromal Tumors* / drug therapy
  • Gastrointestinal Stromal Tumors* / pathology
  • Humans
  • Mutation
  • Naphthyridines / therapeutic use
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Proto-Oncogene Proteins c-kit / genetics
  • Proto-Oncogene Proteins c-kit / therapeutic use
  • Urea / analogs & derivatives
  • Urea / therapeutic use

Substances

  • Antineoplastic Agents
  • Naphthyridines
  • Protein Kinase Inhibitors
  • Urea
  • ripretinib
  • Proto-Oncogene Proteins c-kit